YOLFTbeta
Traws Pharma Inc

Traws Pharma Inc

TRAW · NASDAQ · Healthcare / Biotechnology

0.251USD-0.03 (-11.87%)

Price History

Full chart

Market Stats

Previous Close0.2848
Open0.2822
Day Range0.23 – 0.29
52-Week Range0.4301 – 3.27
Volume531.08K
Market Cap8.90M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.83
Dividend Yield0.00%
Beta1.60
50-Day Avg0.5402
200-Day Avg1.30

About

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Iain D. Dukes DPHIL, M.A., Ph.D.
  • Employees4
  • Headquarters12 Penns Trail, Newtown, PA, United States, 18940, USA
  • Websitehttps://www.trawspharma.com

Leadership

  • Dr. Iain D. Dukes DPHIL, M.A., Ph.D.CEO, Secretary & Director · b. 1958
  • Dr. Nikolay Savchuk Ph.D.COO & Director · b. 1969
  • Dr. Charles David Pauza Ph.D.Chief Scientific Officer of Virology · b. 1955
  • Mr. Charles ParkerChief Financial Officer · b. 1981
  • Dr. Victor Mandia Moyo M.D.Chief Medical Officer of Oncology · b. 1969
  • Dr. Robert R. Redfield M.D.Chief Medical Officer · b. 1952

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.49M46.19M4.75M800.00K11.46M5.55M787.00K1.23M2.18M231.00K226.00K226.00K226.00K226.00K2.79M
Growth (%)-+3006.25%-89.71%-83.17%+1332.00%-51.59%-85.81%+56.04%+77.77%-89.42%-2.16%0.00%0.00%0.00%+1134.51%
Cost of Revenue-319.00K--------14.00K14.00K16.00K12.00K61.00K
Gross Profit1.49M45.87M4.75M800.00K11.46M5.55M787.00K1.23M2.18M231.00K226.00K226.00K226.00K214.00K2.79M
Gross Margin100.00%99.31%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%94.69%100.00%
Operating Expense29.06M68.15M66.97M64.54M35.43M29.25M26.52M24.51M23.88M25.22M16.72M19.85M20.52M49.56M20.66M
Operating Income-27.57M-22.28M-62.22M-63.74M-23.97M-23.70M-25.74M-23.28M-21.70M-24.99M-16.50M-19.63M-20.30M-49.35M-17.88M
Operating Margin-1854.27%-48.23%-1309.11%-7968.00%-209.25%-427.39%-3270.27%-1895.93%-994.00%-10819.48%-7299.12%-8684.51%-8981.42%-21835.40%-640.68%
EBITDA-25.96M-20.98M-61.67M-63.34M-23.86M-19.56M-23.99M-20.48M-21.68M-24.98M-16.48M-19.61M-20.28M-166.51M-17.81M
EBITDA Margin-1745.73%-45.43%-1297.45%-7917.50%-208.25%-352.63%-3048.41%-1667.67%-993.36%-10813.85%-7292.92%-8678.32%-8974.34%-73677.43%-638.49%
Net Income-30.31M-33.87M-64.86M-63.68M-23.98M-19.67M-24.09M-20.57M-21.50M-25.16M-16.16M-18.96M-18.95M-54.67M9.17M
Net Income Margin-2038.60%-73.32%-1364.67%-7960.25%-209.31%-354.62%-3061.25%-1675.33%-985.02%-10890.48%-7151.77%-8391.15%-8384.07%-24192.04%328.67%
R&D22.62M52.76M49.73M49.42M25.89M20.07M19.03M16.87M15.54M16.90M7.30M11.41M11.43M130.31M12.14M
R&D as % of Total Revenue1521.45%114.23%1046.35%6178.13%226.04%361.90%2418.17%1373.70%711.73%7315.15%3228.76%5046.90%5057.52%57659.73%435.23%
Interest Expense19.00K8.61M4.00K2.00K-----------
Interest Expense % of Total Revenue1.28%18.64%0.08%0.25%-----------

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.46M83.85M105.15M47.34M23.45M23.23M4.98M17.92M23.67M19.99M55.48M39.37M22.68M24.96M10.62M
Total Liabilities142.88M242.16M24.25M23.71M12.61M18.11M15.84M12.54M12.10M13.81M9.36M11.06M12.01M56.59M11.25M
Total Equity-138.42M-158.31M80.41M22.75M10.01M4.30M-11.69M5.39M11.57M6.17M46.12M28.31M10.67M-31.63M-629.00K
Cash2.71M81.53M60.01M43.58M19.80M21.45M4.02M16.97M22.73M19.02M55.07M38.76M20.82M21.34M3.82M
Net Debt-2.71M-81.53M-60.01M-43.58M-19.80M-21.45M-4.02M-16.97M-22.73M-19.02M-55.07M-38.76M-20.82M-21.34M-3.82M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-14.17M1.63M-61.38M-57.65M-31.31M-15.81M-23.82M-22.70M-20.83M-23.07M-19.49M-16.29M-17.93M-29.79M-18.18M
Investing Cash Flow-241.00K-279.00K-40.60M39.77M-----55.00K-15.00K---14.00K-3.65M-2.58M
Financing Cash Flow9.79M77.46M80.46M1.46M7.46M17.42M6.36M35.66M26.65M19.36M55.56M0033.98M3.20M
Capital Expenditure256.00K279.00K609.00K228.00K000055.00K15.00K0014.00K02.58M
Free Cash Flow-14.43M1.35M-61.99M-57.88M-31.31M-15.81M-23.82M-22.70M-20.89M-23.09M-19.49M-16.29M-17.95M-29.79M-20.77M
FCF to OCF101.81%82.91%100.99%100.40%100.00%100.00%100.00%100.00%100.26%100.07%100.00%100.00%100.08%100.00%114.22%

Earnings

Report DateSep 6, 2013Nov 12, 2013Mar 11, 2014May 12, 2014Aug 13, 2014Nov 13, 2014Mar 16, 2015May 14, 2015Aug 13, 2015Nov 11, 2015Mar 24, 2016May 11, 2016Aug 15, 2016Nov 14, 2016Mar 27, 2017May 15, 2017Aug 14, 2017Nov 9, 2017Mar 8, 2018May 15, 2018Aug 14, 2018Nov 13, 2018Mar 26, 2019May 14, 2019Aug 14, 2019Nov 12, 2019Mar 24, 2020May 14, 2020Aug 12, 2020Nov 12, 2020Mar 11, 2021May 17, 2021Aug 12, 2021Nov 11, 2021Mar 17, 2022May 11, 2022Aug 11, 2022Nov 14, 2022Mar 16, 2023May 15, 2023Aug 10, 2023Nov 14, 2023Mar 14, 2024Apr 1, 2024Aug 15, 2024Nov 14, 2024Mar 31, 2025May 15, 2025Aug 14, 2025Nov 13, 2025Dec 31, 2025May 15, 2026Aug 14, 2026Nov 12, 2026
EPS Estimate--36806.08--40486.71-46454.09-42649.90-94.00-35437.52-30093.77-15187.51-607.50-10687.51-16650.01-4612.50-15.00-5400.00-4068.75-3895.31-3867.19-0.39-431.25-435.00-0.97-388.12-330.00-255.00-0.07-20.62-11.25-12.50-13.12-0.45-7.12-8.17-0.17-4.69-4.94-5.31-0.26-7.44-7.81-7.25-0.25-6.33-6.25-6.25-0.25-0.27-8.75-9.16-0.54-0.56-0.22-0.21
EPS Actual-35725.79-75375.04-38294.84-48937.52-43312.52-38812.52-0.57-32062.52-23062.51-14625.010.18-15467.07-11064.38-4443.75-0.54-6918.75-1631.25-3993.75-3318.75-5.10-393.75-352.50-0.98-483.75-225.00-281.251.15-11.25-15.00-11.25-11.25-0.30-6.75-5.50-0.17-5.00-4.75-6.50-0.26-7.00-5.00-5.75-0.19-5.00-121.75-8.8126.602.09-0.16-0.34-0.55-0.52-0.16-
Surprise--104.79%--20.87%6.76%9.00%99.39%9.52%23.36%3.70%100.03%-44.72%33.55%3.66%96.40%-28.13%59.91%-2.53%14.18%-1207.69%8.70%18.97%-1.03%-24.64%31.82%-10.29%1742.86%45.44%-33.33%10.00%14.25%33.33%5.20%32.68%0.00%-6.61%3.85%-22.41%0.00%5.91%35.98%20.69%24.00%21.01%-1848.00%-40.96%10740.00%888.68%98.17%96.29%-2.67%7.14%27.27%-
Timing-After-hours-After-hoursAfter-hoursAfter-hours-After-hoursPre-marketAfter-hours-After-hoursPre-marketPre-market-Pre-marketAfter-hoursPre-marketPre-market-Pre-marketPre-market-Pre-marketPre-marketAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hours--Pre-marketPre-market-Pre-marketAfter-hours-

Key Statistics & Ratios

Market Cap8.90M
Enterprise Value2.58M
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.98
Price / Book4.49
EPS-1.83
Book Value0.111
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-21.40M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-433.36%
Return on Assets-99.40%
Shares Outstanding15.37M
Shares Float11.94M
Beta1.60
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 1.00
  • Strong Buy
    1

Ownership Breakdown

Institutions
40.06%
Insiders
5.43%
Retail / Other
54.51%

Top Institutional Holders

  • Ally Bridge Group (NY) LLC
    786.24K5.12%
  • Adage Capital Partners Gp LLC
    730.00K4.75%
  • Ikarian Capital, LLC
    678.14K4.41%
  • Orbimed Advisors LLC
    605.53K3.94%
  • Lynx1 Capital Management, LP
    559.47K3.64%
  • Dauntless Investment Group, LLC
    417.00K2.71%
  • BOOTHBAY FUND MANAGEMENT, LLC
    194.54K1.27%
  • ADAR1 Capital Management LLC
    154.10K1.00%
  • Kynam Capital Management, LP
    84.40K0.55%
  • Geode Capital Management, LLC
    77.10K0.50%
  • Palumbo Wealth Management LLC
    61.17K0.40%
  • Vanguard Capital Management, LLC
    55.19K0.36%
  • Vanguard Fiduciary Trust Co
    31.80K0.21%
  • State Street Corp
    25.80K0.17%
  • Jane Street Group LLC
    21.24K0.14%
  • BlackRock Inc
    9.96K0.06%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    177.20K1.15%
  • Fidelity Extended Market Index
    73.91K0.48%
  • Fidelity Nasdaq Composite Index
    17.60K0.11%
  • Fidelity Series Total Market Index
    8.10K0.05%

Stock Splits

  • Sep 23, 20241:25
  • May 21, 20211:15
  • Sep 26, 20181:15
  • Jun 1, 20161:10